Somewhat Positive Media Coverage Somewhat Unlikely to Impact Heska Corporation (HSKA) Share Price
News stories about Heska Corporation (NASDAQ:HSKA) have trended somewhat positive this week, Accern reports. The research firm rates the sentiment of news coverage by analyzing more than twenty million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Heska Corporation earned a media sentiment score of 0.15 on Accern’s scale. Accern also assigned media coverage about the medical research company an impact score of 45.2564666378693 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the near term.
Heska Corporation (NASDAQ HSKA) traded down 0.71% during trading on Friday, hitting $88.09. The company had a trading volume of 76,912 shares. The stock has a market capitalization of $636.54 million, a price-to-earnings ratio of 44.90 and a beta of 0.91. Heska Corporation has a 1-year low of $46.51 and a 1-year high of $115.00. The company’s 50 day moving average price is $98.08 and its 200-day moving average price is $98.84.
Heska Corporation (NASDAQ:HSKA) last posted its quarterly earnings results on Thursday, August 3rd. The medical research company reported $0.44 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.37 by $0.07. Heska Corporation had a return on equity of 15.87% and a net margin of 10.70%. The business had revenue of $34.30 million for the quarter, compared to analyst estimates of $33.35 million. During the same period last year, the company earned $0.35 EPS. Heska Corporation’s revenue for the quarter was up 14.3% compared to the same quarter last year. On average, analysts expect that Heska Corporation will post $2.04 EPS for the current year.
A number of equities analysts recently commented on the company. B. Riley reaffirmed a “neutral” rating and issued a $85.00 price objective on shares of Heska Corporation in a research note on Friday, July 28th. BidaskClub lowered Heska Corporation from a “buy” rating to a “hold” rating in a research note on Sunday, July 16th. Aegis lifted their price objective on Heska Corporation from $114.50 to $129.50 and gave the stock a “buy” rating in a research note on Tuesday, August 1st. Benchmark Co. reaffirmed a “buy” rating and issued a $120.00 price objective (up from $106.00) on shares of Heska Corporation in a research note on Wednesday, August 9th. Finally, Zacks Investment Research raised Heska Corporation from a “hold” rating to a “buy” rating and set a $109.00 price objective on the stock in a research note on Friday, August 4th. Four research analysts have rated the stock with a hold rating and three have issued a buy rating to the company. The company currently has a consensus rating of “Hold” and a consensus price target of $105.20.
In other news, EVP Nancy Wisnewski sold 825 shares of Heska Corporation stock in a transaction that occurred on Thursday, August 31st. The stock was sold at an average price of $102.21, for a total value of $84,323.25. Following the sale, the executive vice president now directly owns 38,114 shares in the company, valued at approximately $3,895,631.94. The sale was disclosed in a filing with the SEC, which is available through this link. Also, CFO John Mcmahon sold 2,608 shares of Heska Corporation stock in a transaction that occurred on Wednesday, August 30th. The stock was sold at an average price of $101.17, for a total value of $263,851.36. Following the completion of the sale, the chief financial officer now owns 193 shares in the company, valued at $19,525.81. The disclosure for this sale can be found here. 14.70% of the stock is currently owned by company insiders.
About Heska Corporation
Heska Corporation sells veterinary diagnostic and specialty products. The Company operates through two segments: Core Companion Animal Health (CCA) and Other Vaccines, Pharmaceuticals and Products (OVP). The CCA segment includes, primarily for canine and feline use, blood testing instruments and supplies, digital imaging products, software and services, local and cloud-based data services, allergy testing and immunotherapy, and single use offerings, such as in-clinic diagnostic tests and heartworm preventive products.
Receive News & Ratings for Heska Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heska Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.